Victory Capital Management Inc. Grows Stake in LivaNova PLC (NASDAQ:LIVN)

Victory Capital Management Inc. lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 16.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 935,102 shares of the company’s stock after purchasing an additional 133,401 shares during the period. Victory Capital Management Inc. owned about 1.72% of LivaNova worth $49,130,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Hexagon Capital Partners LLC grew its stake in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares in the last quarter. Fifth Third Bancorp grew its stake in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares in the last quarter. Lazard Asset Management LLC acquired a new position in LivaNova in the 1st quarter valued at about $84,000. Canada Pension Plan Investment Board acquired a new position in LivaNova in the 2nd quarter valued at about $88,000. Finally, Acadian Asset Management LLC acquired a new position in LivaNova in the 1st quarter valued at about $94,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on LIVN shares. Robert W. Baird boosted their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. The Goldman Sachs Group began coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Tuesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

LivaNova stock opened at $52.10 on Friday. The firm has a market cap of $2.83 billion, a PE ratio of 124.05 and a beta of 1.01. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average is $51.67 and its two-hundred day moving average is $52.98.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.